Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-31

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial will assess the tolerability and safety of AFX-2 over a range of five dose levels in adults with low-, intermediate- or high-risk Chronic Lymphocytic Leukemia (CLL). The trial will also determine the impact of dose on quality of life indices and on biological and immune responses, and will assess if there is a maximum tolerated dose and/or dose-limiting toxicity in this study population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

NCT04771572

Non Hodgkin Lymphoma Richter Transformation Multiple Myeloma +10 more

RECRUITING PHASE1

CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

NCT05260528

Acute Myeloid Leukemia

RECRUITING PHASE2

Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)

NCT00684918

AML

COMPLETED PHASE2

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia

NCT01627054

Chronic Lymphocytic Leukemia

COMPLETED PHASE2

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

NCT05944978

Relapsed/Refractory Chronic Lymphocytic Leukemia

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia, Lymphocytic, Chronic, B-Cell

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Dose level 1

Intervention Type DRUG

AFX-2

Dose level 2

Intervention Type DRUG

AFX-2

Dose level 3

Intervention Type DRUG

AFX-2

Dose level 4

Intervention Type DRUG

AFX-2

Dose level 5

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult men and women \>18 years of age
2. Diagnosis of CLL per NCI Working Group Criteria; with phenotypic evidence (i.e.. flow cytometry or bone marrow biopsy) of chronic lymphocytic leukemia (MEDDRA Code - 10008960; ICD-O3-9823)
3. Disease meets criteria for low-risk (Rai Stage 0), intermediate-risk (Rai Stage I- II), or high-risk (Rai Stage III-IV) disease
4. Life expectancy of ≥ 3 months at Screening.
5. ECOG performance status 0-3
6. Laboratory parameters (taken \< 14 days of Study Day 0):

* Hematologic parameters: Hemoglobin \> 9 gm/dL (stable, not dropping); Absolute Granulocyte Count (AGC) \> 1.0 x 109/L; Platelets \> 50 x 109/L; not requiring immediate transfusion.
* Coagulation: PT/PTT/INR: ± 10% of NL for lab; INR: 1.0-1.43
* BUN \< 40; serum Creatinine ≤ 2.0 mg/dL, OR Creatinine Clearance \> 90 mL/min/1.73m2 IF serum Creatinine \> 2.0 mg/dL
* Liver function tests (AST, ALT, ALP, LDH): \< 2.5 x institutional ULN; Total bilirubin: \< 2.0 x institutional ULN
* Human Immunodeficiency Virus (HIV) negative
* Pregnancy test: negative urine pregnancy test for females of child-bearing potential,
7. Free of disease from prior malignancy/ies for \> 2 years, except for basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.
8. If not surgically sterile, or post-menopausal (\> 12 months with no menstrual flow), willing to practice birth control (barrier + contraception) throughout duration of study.
9. Able and willing to swallow capsules.
10. Willing to limit alcohol intake during the study treatment period.
11. Willing to sign the informed consent.

Exclusion Criteria

1. Lymphoproliferative disease other than CLL
2. Prior use of the test article (AFX-2), or ginseng-containing products (American, Asian, etc.) ≤ 1 year prior to study entry.
3. Known allergy to the test article or ginseng-containing products
4. Active infection requiring systemic treatment
5. Prior or current therapy:

* Splenectomy.
* Currently requiring anticoagulant therapy
* Requiring active treatment for B-CLL or ≤ 28 days post-treatment for B-CLL or other condition requiring: chemotherapy, radiation therapy, monoclonal antibodies, systemic steroids, antihistamines or non-steroidal anti-inflammatory drugs, including ibuprofen, indomethacin, COX-2 inhibitors etc.
* ≤ 10 days: non-steroidal hormonal therapy (other than for contraception or thyroid)
* ≤ 10 days: antibiotic prophylaxis
* History of therapy with immunological reagents, such as allogeneic bone marrow transplant, monoclonal antibody therapy, intravenous immunoglobulin, or hematopoietic stem cell transplantation. (Note: Immunotherapy for allergies is permitted as long as the last treatment was both (a) prior to the CLL diagnosis and (b) \> 5 years prior to trial enrollment.)
* \< 90 days post treatment with chlorambucil
* \< 90 days post general anesthesia
6. Uncontrolled intercurrent condition, including, but not limited to, cardiovascular, pulmonary, renal, hepatic, GI, GU, neurologic, metabolic, psychiatric, etc.
7. Current or prior investigational product or procedure \< 56 days preceding study entry (Baseline -Visit 2; Study Day 0).
8. Unwilling to discontinue use of nonprescription (OTC), nutritional or dietary supplements during the study period (as further defined by protocol).
9. Pregnant, lactating.
10. Any condition, personal or social situation that precludes or limits the ability of the participant to provide informed consent or comply with study requirements.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No